Lupin has entered into the prescription dermatology segment in Brazil with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella. Valued at $28 billion, Brazil is the world's 6th largest pharmaceutical market, driven by growing public health expenditure and increasing household income. The dermatology segment in Brazil, worth $1.5 billion, and growing at 10% (CAGR) is one of the fastest growing segments in the country.
As part of the launch, Lupin has also launched a 360-degree communications campaign, focused on healthcare professionals, pharmacy chains and regional and national medical associations in Brazil.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
